Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Biogen Price Targets Lowered Across the Board

Published 21/10/2021, 16:16
Updated 21/10/2021, 16:16
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com — Several analysts cut their price targets on Biogen Inc's (NASDAQ:BIIBshares after concerns about Aduhelm sales following the company's third quarter earnings report.

The biotechnology firm posted a revenue and EPS beat on Wednesday morning. Revenue came in at $2.78 billion, above the consensus of $2.67 billion, while its EPS was reported at $4.77, above the expected $4.11. 

However, it sold just $300,000 worth of its controversial Alzheimer's drug Aduhelm, falling way short of analyst predictions. 

Oppenheimer analyst Jay Olson reduced the firm's price target on Biogen to $390 from $450 but kept an outperform rating on the shares. Likewise, Cowen's Phil Nadeau dropped his firm's price target on Biogen to $375 from $450 with an outperform rating, as did RBC Capital analyst Brian Abrahams, who lowered the price target on Biogen to $295 from $325, and Piper Sandler analyst Christopher Raymond lowered Biogen's price target to $390 from $460, keeping an overweight rating.

All four analysts cited the sales of Aduhelm as the reason for the price target decrease, with Piper Sandler's Raymond stating that the Aduhelm launch was "even worse than feared."

However, despite the downgrades, Biogen's share price has remained resilient, up over 1.2% on Thursday, following Wednesday's 0.58% decline. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.